Search clinical trials for: OC-01 (varenicline) nasal spray 1.2 mg/ml

Total 29 results

Oyster Point Pharma, Inc.

Completed

Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

Long Term Follow up Dry Eye Disease

United States
Oyster Point Pharma, Inc.

Completed

Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study)

Dry Eye Disease

Mexico
Oyster Point Pharma, Inc.

Completed

Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline

Healthy Subjects

United States
Oyster Point Pharma, Inc.

Completed

Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy

Neurotrophic Keratopathy

United States
Oyster Point Pharma, Inc.

Completed

Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)

Dry Eye Disease

United States
Oyster Point Pharma, Inc.

Completed

Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)

Dry Eye Disease

United States
Brandon Baartman

Recruiting

Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Photorefractive Keratectomy (PRK)

Dry Eye

United States
Vance Thompson Vision - MT

Not yet recruiting

IIT Assessing OC-01Nasal Spray on Symptoms of DED Following CXL

Dry Eye Disease

United States
Center for Ophthalmic and Vision Research, LLC

Completed

OC-01 (Varenicline) Nasal Spray and Dry Eye Signs and Symptoms in Daily Disposable Contact Lens Wearers

Dry Eye

United States
Vance Thompson Vision ND

Completed

Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)

Dry Eye Disease

United States
Oyster Point Pharma, Inc.

Completed

Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

Dry Eye Disease (DED)

United States
Oyster Point Pharma, Inc.

Completed

Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

Dry Eye Disease

United States
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
Oyster Point Pharma, Inc.

Completed

Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease

Dry Eye Disease

China
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
Oyster Point Pharma, Inc.

Completed

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of OC-01 in Adult Chinese With Dry Eye Disease

Dry Eye Disease

China
Stephenson Eye Associates

Recruiting

A Randomized, Controlled, Double-masked, Investigator-initiated Trial to Evaluate Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray (TSUNAMI)

Dry Eye Disease

United States
Oyster Point Pharma, Inc.

Completed

Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation

Dry Eye Disease

United States
NPO Petrovax

Completed

Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI

Acute Respiratory Infection

Russian Federation
El Instituto Nacional de Neurologia y Neurocirugia...
Howard University

Completed

Pilot Trial of Transnasal Nicotine in Parkinson Disease

Parkinson Disease

Mexico
Zosano Pharma Corporation

Completed

A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers

Migraine

United States
Centre hospitalier de l'Université de Montréal...

Active, not recruiting

Dupilumab for Prevention of Recurrence of CRSwNP After ESS

Chronic Rhinosinusitis With Nasal Polyps

Canada
University Health Network, Toronto

Recruiting

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients (HALLMARK)

Kidney Transplant Recipients

Canada
Leiden University Medical Center
U.S. Food and Drug Administration (FDA)

Recruiting

Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists (ROAR)

Chronic Opioid Use | Opioid Induced Respiratory Depression

Netherlands
Zagazig University

Completed

Nasal Desmopressin Versus Topical Epinephrine in Endonasal Dacryocystorhinostomy

Anesthesia

Egypt
Université de Sherbrooke

Terminated

Mometasone vs Budesonide in CRS With Polyposis

Chronic Rhinosinusitis (Diagnosis), Nasal Polyposis

Canada
Oculis

Completed

OCS-01 in Treating Inflammation and Pain in Post-cataract Patients (SKYGGN)

Pain, Postoperative | Inflammation Corneal

United States
Karolinska Institutet

Terminated

Goal Directed Haemodynamic Treatment for Patients With Proximal Femoral Fracture (GDHT)

Femoral Fracture

Sweden
Assaf-Harofeh Medical Center

Recruiting

Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High Responders

Ovarian Hyperstimulation Syndrome | Miscarriage | Pregnancy Early

Israel
Wuhan Union Hospital, China

Withdrawn

Prophylactic Effects of Esketamine in Surgical Patients

Surgical Injury

China
Wuhan Union Hospital, China

Recruiting

Esketamine Induction Intubation in ICU Patients.

Critically Ill Patients

China

3

Subscribe